Zealand Pharma’s newly inked deal with Novo Nordisk is just one of many that the Danish biotech company intends to sign over the next few years. In March, Zealand Pharma changed its strategy to focus on research and development, choosing to let other companies take charge of future commercialization efforts.
The pivot followed the company’s realization that building a sales organization is a costly affair, which is why Zealand Pharma sold the rights earlier this year for its insulin pump, V-Go, for USD 10m to Mannkind, and on Wednesday traded the rights rights to rescue pen Zegalogue (dasiglucagon) with Novo Nordisk in a deal that cold run up to DKK 290m (USD 38.7m) when future milestones are counted.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
FDA fast-tracks Eli Lilly's obesity candidate
Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.
Jefferies spots weaknesses in GN
One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.
Bavarian initiates new arm of phase III Covid-19 vaccine trial
The first patient has already been dosed in the US, and the Danish vaccine maker is now expanding the study to include Denmark and Belgium.
Life science CEOs' paychecks decrease as markets decline
When the markets are down, everyone is in the same boat, in theory -- however, former Ambu CEO Lars Marcher warns boards against unduly rewarding CEOs by changing pre-existing share-based programs.
Fujifilm doubles bottom line in annual report
Despite a 12.5% cost increase compared to the preceding year, Fujifilm Diosynth Biotechnologies managed to increase its profit twofold in 2021/2022.
Senior Director Translational Pharmacology 
Nordic Key Account Manager, Hollister & Dansac 
Upstream Processing CMC Specialist 
Clinical Trial Supplies Senior Professional 
Experienced IT Business Solutions Manager for the Danish Medicines Agency 
KLIFO is looking for QA Specialist/Senior QA Specialist, GCP and GVP for our Glostrup office 
Head of department RA/QA/PV, Danmark 
Drug Safety Associate 
Clinical Project Lead 
Pharmacovigilance & Regulatory Officer 
Senior/lead consultant at Emendo Engineering 
Scientist Radiochemistry 
Product specialist 
Orifarm Healthcare Product Development PMO Director